1. Gene expression profile at week 2 of neoadjuvant therapy course predicts outcome in HER2-positive breast cancer patients: an explorative analysis from NeoALTTO. (November 2022) Authors: Di Cosimo, S.; Pizzamiglio, S.; Sotiriou, C.; Ciniselli, C.M.; Triulzi, T.; de Cecco, L.; El-Abed, S.; Izquierdo, M.; de Azambuja, E.; Saura, C.; Huober, J.; Untch, M.; Lang, I.; Loi, S.; Tagliabue, E.; Rubio, I.T.; Vingiani, A.; Colombo, M.P.; Verderio, P.; Pruneri, G. Journal: European journal of cancer Issue: Volume 175(2022)Supplement 1 Page Start: S78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. (January 2018) Authors: Di Cosimo, S.; Campbell, C.; Azim, H.A.; Galli, G.; Bregni, G.; Curigliano, G.; Criscitiello, C.; Izquierdo, M.; de la Pena, L.; Fumagalli, D.; Fein, L.; Vinholes, J.; Ng, W.M.J.; Colleoni, M.; Ferro, A.; Naume, B.J.; Patel, A.; Huober, J.; Piccart-Gebhart, M.J.; Baselga, J. Journal: European journal of cancer Issue: Volume 89(2018) Page Start: 42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. (June 2017) Authors: Solinas, C.; Ceppi, M.; Lambertini, M.; Scartozzi, M.; Buisseret, L.; Garaud, S.; Fumagalli, D.; de Azambuja, E.; Salgado, R.; Sotiriou, C.; Willard-Gallo, K.; Ignatiadis, M. Journal: Cancer treatment reviews Issue: Volume 57(2017) Page Start: 8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗